🚀 VC round data is live in beta, check it out!
Shanghai RAAS Valuation Multiples
Discover revenue and EBITDA valuation multiples for Shanghai RAAS and similar public comparables like Henlius Biotech, Gan and Lee, Beijing Tongrentang, Caliway Biopharmaceuticals and more.
Shanghai RAAS Overview
About Shanghai RAAS
Shanghai RAAS Blood Products Co Ltd is a blood products manufacturer in China that has a high comprehensive utilization of plasma raw materials and different specifications. It is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. The main products are human albumin, intravenous human immunoglobulin, coagulation factor products, etc.
Founded
1988
HQ
Employees
3.4K
Website
Sectors
Financials (FY)
EV
$6B
Shanghai RAAS Financials
Shanghai RAAS reported last fiscal year revenue of $1B and EBITDA of $320M.
In the same fiscal year, Shanghai RAAS generated $402M in gross profit, $320M in EBITDA, and $231M in net income.
Revenue (LTM)
Shanghai RAAS P&L
In the most recent fiscal year, Shanghai RAAS reported revenue of $1B and EBITDA of $320M.
Shanghai RAAS expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $402M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA | — | XXX | $320M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 23% | XXX | XXX | XXX |
| Net Profit | — | XXX | $231M | XXX | XXX | XXX |
| Net Margin | — | XXX | 21% | XXX | XXX | XXX |
| Net Debt | — | — | $349M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Shanghai RAAS Stock Performance
Shanghai RAAS has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
Shanghai RAAS's stock price is $0.84.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | -1.5% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialShanghai RAAS Valuation Multiples
Shanghai RAAS trades at 5.5x EV/Revenue multiple, and 18.5x EV/EBITDA.
EV / Revenue (LTM)
Shanghai RAAS Financial Valuation Multiples
As of April 10, 2026, Shanghai RAAS has market cap of $6B and EV of $6B.
Equity research analysts estimate Shanghai RAAS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shanghai RAAS has a P/E ratio of 24.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 18.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 24.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 14.7x | XXX | XXX | XXX |
| P/E | — | XXX | 24.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (57.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Shanghai RAAS Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Shanghai RAAS Margins & Growth Rates
Shanghai RAAS's revenue in the last fiscal year declined by (10%).
Shanghai RAAS's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.
Shanghai RAAS Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (10%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (23%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Shanghai RAAS Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Henlius Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Gan and Lee | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Tongrentang | XXX | XXX | XXX | XXX | XXX | XXX |
| Caliway Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hebei Changshan | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai RAAS M&A Activity
Shanghai RAAS acquired XXX companies to date.
Last acquisition by Shanghai RAAS was on XXXXXXXX, XXXXX. Shanghai RAAS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Shanghai RAAS
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialShanghai RAAS Investment Activity
Shanghai RAAS invested in XXX companies to date.
Shanghai RAAS made its latest investment on XXXXXXXX, XXXXX. Shanghai RAAS invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Shanghai RAAS
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Shanghai RAAS
| When was Shanghai RAAS founded? | Shanghai RAAS was founded in 1988. |
| Where is Shanghai RAAS headquartered? | Shanghai RAAS is headquartered in China. |
| How many employees does Shanghai RAAS have? | As of today, Shanghai RAAS has over 3K employees. |
| Is Shanghai RAAS publicly listed? | Yes, Shanghai RAAS is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Shanghai RAAS? | Shanghai RAAS trades under 002252 ticker. |
| When did Shanghai RAAS go public? | Shanghai RAAS went public in 2008. |
| Who are competitors of Shanghai RAAS? | Shanghai RAAS main competitors are Henlius Biotech, Gan and Lee, Beijing Tongrentang, Caliway Biopharmaceuticals. |
| What is the current market cap of Shanghai RAAS? | Shanghai RAAS's current market cap is $6B. |
| What is the current revenue of Shanghai RAAS? | Shanghai RAAS's last fiscal year revenue is $1B. |
| What is the current EV/Revenue multiple of Shanghai RAAS? | Current revenue multiple of Shanghai RAAS is 5.5x. |
| Is Shanghai RAAS profitable? | No, Shanghai RAAS is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.